Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06451770 | Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia | PHASE1 | RECRUITING | 36 | — | — | Oct 30, 2024 | Dec 1, 2027 | Apr 28, 2026 | 10 | Australia, Canada +2 |
| Arm | Type | Description |
|---|---|---|
| Cohort 1: Single Ascending Dose Escalation | EXPERIMENTAL | Participants will receive a single dose of VERVE-201. |
| Cohort 2: Single Ascending Dose Escalation | EXPERIMENTAL | Participants will receive a single dose of VERVE-201. |
| Cohort 3: Single Ascending Dose Escalation | EXPERIMENTAL | Participants will receive a single dose of VERVE-201. |
| Cohort 4: Single Ascending Dose Escalation | EXPERIMENTAL | Participants will receive a single dose of VERVE-201. |
| Cohort 5: Single Ascending Dose Escalation | EXPERIMENTAL | Participants will receive a single dose of VERVE-201. |
| Cohort 6: Single Ascending Dose Escalation | EXPERIMENTAL | Participants will receive a single dose of VERVE-201. |
| Name | Type | Description |
|---|---|---|
| VERVE-201 | DRUG | Intravenous (IV) infusion |
Inclusion Criteria: * Refractory hypercholesterolemia * Refractory hypertriglyceridemia Exclusion Criteria: * Active or history of chronic liver disease * Current treatment with monoclonal antibody targeting ANGPTL3 or prior treatment within specified timeframe * Clinically significant or abnorma...